Table 1.

Pharmacoepidemiologic screening: summary of case characteristics and results

	Glimepiride	Glipizide	Glyburide	Nateglinide	Repaglinide	Metformin
Cases
Number	1,270	1,755	1,698	77	118	1,885
Female (%)	57.3	57.7	55.8	42.9	42.4	54
Median age (years)	72.6	72.8	72.9	73.8	73.4	68.8
Observed person-days	266,196	392,760	347,411	7,415	11,800	302,616
Number of events	2,244	2,832	2,903	106	183	2,707
Cases (%) receiving prescription(s) for antidiabetics other than the secretagogues in the 30 days prior to events
Nonea	56.4	53	47.3	54.7	44.8	14.9
Metformin only	14.5	17.5	28.9	8.5	17.5	46.4
Insulin only	9.5	12.3	6.2	16	17.5	3.9
Other antidiabeticsb	9.8	7.1	6.5	4.7	6.5	0.4
Insulin + metformin	2.8	3.5	3.4	1	4.4	20.8
Metformin + other antidiabetics	5.3	4.1	5.3	2.8	4.4	8.2
Insulin + other antidiabetics	1.2	1.7	0.8	11.3	2.7	0.3
Insulin + metformin + other antidiabetics	0.5	0.8	1.6	1	2.2	5.1
RRSB estimates
Number of precipitants examined	218	222	228	39	69	220
Geometric mean ± SD	1.27 ± 1.54	1.28 ± 1.50	1.26 ± 1.53	1.11 ± 1.37	1.39 ± 1.72	1.16 ± 1.37
Range	0.42 – 4.74	0.31 – 5.03	0.40 – 5.61	0.44 – 1.77	0.38 – 3.74	0.50 – 2.61
Number of statistically significant RRSB >1	47	41	43	0	9	30
Metformin adjusted RRSB estimates
Number of precipitants examined	181	187	191	38	67	N/A
Geometric mean ± SD	1.07 ± 1.83	1.06 ± 1.86	1.03 ± 1.87	1.09 ± 1.87	1.41 ± 2.33
Range	0.2 – 5.53	0.15 – 6.75	0.22 – 5.57	0.28 – 3.39	0.24 – 15.62
Number of statistically significant RRSB >1	16	18	17	0	10

^aInclude patients who filled prescriptions for the study secretagogues or metformin earlier than 30 days prior to events and had active prescription during the 30 days according to day’s supply.

^bOther antidiabetics included thiazolidinediones, sulfonylureas other than glyburide, glipizide and glimepiride, glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitor, alpha-glucosidase inhibitors, sodium/glucose cotransporter 2 inhibitors, and amylin analogs.